Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.

Search results

Showing results for

Enquire now

Join the BioEscalator mailing list

Similar stories

Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151

PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data

Let’s just get married – the story of an acquisition

Explore

Information